Skip to main content
. Author manuscript; available in PMC: 2019 Dec 7.
Published in final edited form as: Circ Res. 2018 Dec 7;123(12):1285–1297. doi: 10.1161/CIRCRESAHA.118.313089

Figure 7. Myofibroblast specific ablation of Tgfbr2 (r2) preserves cardiac function and prolongs Mybpc340kDa mouse survival.

Figure 7.

A-C, Echocardiographic analyses of 6-month-old nontransgenic (Ntg)- and Mybpc340kDa-expressing (Dtg) hearts as well as heterozygote (r2f/+) and homozygote (r2f/f) nulls of Tgfbr2 crossed into the Dtg background. One-way ANOVA analysis with Tukey’s post hoc test, **P<0.01, ***P<0.001, comparing to Ntg, no tamoxifen (TAM) group; ###P<0.001, between group comparison, n=6–11. D, Kaplan-Meier survival curve. P<0.0001 using the Log-rank test, n=7–23; all between group comparisons were performed using the Holm-Šídák post hoc test, *P<0.05. FS; fractional shortening, EF; ejection fraction, rLSR; reverse peak longitudinal strain rate.